Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine

Maojun Yang, Jeffrey C. Culhane, Lawrence M. Szewczuk, Pegah Jalili, Haydn L. Ball, Mischa Machius, Philip A. Cole, Hongtao Yu

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Histone modifications, such as acetylation and methylation, are important epigenetic marks that regulate diverse biological processes that use chromatin as the template, including transcription. Dysregulation of histone acetylation and methylation leads to the silencing of tumor suppressor genes and contributes to cancer progression. Inhibitors of enzymes that catalyze the addition and removal of these epigenetic marks thus have therapeutic potential for treating cancer. Lysine-specific demethylase 1 (LSD1) is the first discovered histone lysine demethylase and, with the help of its cofactor CoREST, specifically demethylates mono- and dimethylated histone H3 lysine 4 (H3-K4), thus repressing transcription. Because LSD1 belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used antidepressant trans-2-phenylcyclopropylamine (PCPA; tranylcypromine; Parnate), are also capable of inhibiting LSD1. In this study, we have further measured the kinetic parameters of the inhibition of LSD1 by PCPA and determined the crystal structure of LSD1-CoREST in the presence of PCPA. Our structural and mass spectrometry analyses are consistent with PCPA forming a covalent adduct with FAD in LSD1 that is distinct from the FAD-PCPA adduct of MAO B. The structure also reveals that the phenyl ring of the FAD-PCPA adduct in LSD1 does not form extensive interactions with active-site residues. This study thus provides the basis for designing more potent inhibitors of LSD1 that contain substitutions on the phenyl ring of PCPA to fully engage neighboring residues.

Original languageEnglish (US)
Pages (from-to)8058-8065
Number of pages8
JournalBiochemistry
Volume46
Issue number27
DOIs
StatePublished - Jul 10 2007

Fingerprint

Histone Demethylases
Tranylcypromine
Antidepressive Agents
Lysine
Flavin-Adenine Dinucleotide
Histones
Acetylation
Methylation
Transcription
Epigenomics
Histone Code
Biological Phenomena
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Enzyme Inhibitors
Tumor Suppressor Genes
Kinetic parameters
Chromatin
Amines
Mass spectrometry

ASJC Scopus subject areas

  • Biochemistry

Cite this

Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. / Yang, Maojun; Culhane, Jeffrey C.; Szewczuk, Lawrence M.; Jalili, Pegah; Ball, Haydn L.; Machius, Mischa; Cole, Philip A.; Yu, Hongtao.

In: Biochemistry, Vol. 46, No. 27, 10.07.2007, p. 8058-8065.

Research output: Contribution to journalArticle

Yang, Maojun ; Culhane, Jeffrey C. ; Szewczuk, Lawrence M. ; Jalili, Pegah ; Ball, Haydn L. ; Machius, Mischa ; Cole, Philip A. ; Yu, Hongtao. / Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. In: Biochemistry. 2007 ; Vol. 46, No. 27. pp. 8058-8065.
@article{43b16be391bb47168783cd908ab7cdff,
title = "Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine",
abstract = "Histone modifications, such as acetylation and methylation, are important epigenetic marks that regulate diverse biological processes that use chromatin as the template, including transcription. Dysregulation of histone acetylation and methylation leads to the silencing of tumor suppressor genes and contributes to cancer progression. Inhibitors of enzymes that catalyze the addition and removal of these epigenetic marks thus have therapeutic potential for treating cancer. Lysine-specific demethylase 1 (LSD1) is the first discovered histone lysine demethylase and, with the help of its cofactor CoREST, specifically demethylates mono- and dimethylated histone H3 lysine 4 (H3-K4), thus repressing transcription. Because LSD1 belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used antidepressant trans-2-phenylcyclopropylamine (PCPA; tranylcypromine; Parnate), are also capable of inhibiting LSD1. In this study, we have further measured the kinetic parameters of the inhibition of LSD1 by PCPA and determined the crystal structure of LSD1-CoREST in the presence of PCPA. Our structural and mass spectrometry analyses are consistent with PCPA forming a covalent adduct with FAD in LSD1 that is distinct from the FAD-PCPA adduct of MAO B. The structure also reveals that the phenyl ring of the FAD-PCPA adduct in LSD1 does not form extensive interactions with active-site residues. This study thus provides the basis for designing more potent inhibitors of LSD1 that contain substitutions on the phenyl ring of PCPA to fully engage neighboring residues.",
author = "Maojun Yang and Culhane, {Jeffrey C.} and Szewczuk, {Lawrence M.} and Pegah Jalili and Ball, {Haydn L.} and Mischa Machius and Cole, {Philip A.} and Hongtao Yu",
year = "2007",
month = "7",
day = "10",
doi = "10.1021/bi700664y",
language = "English (US)",
volume = "46",
pages = "8058--8065",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "27",

}

TY - JOUR

T1 - Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine

AU - Yang, Maojun

AU - Culhane, Jeffrey C.

AU - Szewczuk, Lawrence M.

AU - Jalili, Pegah

AU - Ball, Haydn L.

AU - Machius, Mischa

AU - Cole, Philip A.

AU - Yu, Hongtao

PY - 2007/7/10

Y1 - 2007/7/10

N2 - Histone modifications, such as acetylation and methylation, are important epigenetic marks that regulate diverse biological processes that use chromatin as the template, including transcription. Dysregulation of histone acetylation and methylation leads to the silencing of tumor suppressor genes and contributes to cancer progression. Inhibitors of enzymes that catalyze the addition and removal of these epigenetic marks thus have therapeutic potential for treating cancer. Lysine-specific demethylase 1 (LSD1) is the first discovered histone lysine demethylase and, with the help of its cofactor CoREST, specifically demethylates mono- and dimethylated histone H3 lysine 4 (H3-K4), thus repressing transcription. Because LSD1 belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used antidepressant trans-2-phenylcyclopropylamine (PCPA; tranylcypromine; Parnate), are also capable of inhibiting LSD1. In this study, we have further measured the kinetic parameters of the inhibition of LSD1 by PCPA and determined the crystal structure of LSD1-CoREST in the presence of PCPA. Our structural and mass spectrometry analyses are consistent with PCPA forming a covalent adduct with FAD in LSD1 that is distinct from the FAD-PCPA adduct of MAO B. The structure also reveals that the phenyl ring of the FAD-PCPA adduct in LSD1 does not form extensive interactions with active-site residues. This study thus provides the basis for designing more potent inhibitors of LSD1 that contain substitutions on the phenyl ring of PCPA to fully engage neighboring residues.

AB - Histone modifications, such as acetylation and methylation, are important epigenetic marks that regulate diverse biological processes that use chromatin as the template, including transcription. Dysregulation of histone acetylation and methylation leads to the silencing of tumor suppressor genes and contributes to cancer progression. Inhibitors of enzymes that catalyze the addition and removal of these epigenetic marks thus have therapeutic potential for treating cancer. Lysine-specific demethylase 1 (LSD1) is the first discovered histone lysine demethylase and, with the help of its cofactor CoREST, specifically demethylates mono- and dimethylated histone H3 lysine 4 (H3-K4), thus repressing transcription. Because LSD1 belongs to the family of flavin adenine dinucleotide (FAD)-dependent amine oxidases, certain inhibitors of monoamine oxidases (MAOs), including the clinically used antidepressant trans-2-phenylcyclopropylamine (PCPA; tranylcypromine; Parnate), are also capable of inhibiting LSD1. In this study, we have further measured the kinetic parameters of the inhibition of LSD1 by PCPA and determined the crystal structure of LSD1-CoREST in the presence of PCPA. Our structural and mass spectrometry analyses are consistent with PCPA forming a covalent adduct with FAD in LSD1 that is distinct from the FAD-PCPA adduct of MAO B. The structure also reveals that the phenyl ring of the FAD-PCPA adduct in LSD1 does not form extensive interactions with active-site residues. This study thus provides the basis for designing more potent inhibitors of LSD1 that contain substitutions on the phenyl ring of PCPA to fully engage neighboring residues.

UR - http://www.scopus.com/inward/record.url?scp=34447338875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447338875&partnerID=8YFLogxK

U2 - 10.1021/bi700664y

DO - 10.1021/bi700664y

M3 - Article

C2 - 17569509

AN - SCOPUS:34447338875

VL - 46

SP - 8058

EP - 8065

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 27

ER -